Fatigue News and Research

RSS

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).

17 Jul 2012

Stress management treatment reduces formation of new brain lesions in people with MS

Research conducted by Jesus Lovera, MD, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has shown that stress management treatment significantly reduced the formation of new brain lesions in people with multiple sclerosis (MS) over the course of treatment.

17 Jul 2012

Migraine involves multiple symptoms that vary widely among sufferers

Almost everyone suffers from headache pain occasionally, but for 36 million Americans, intense, debilitating headaches accompanied by other neurological symptoms — also known as migraine syndrome — are a source of physical misery that can have a devastating effect on their quality of life. It is estimated that the medical expenses and loss of productivity caused by migraine costs Americans $20 billion annually.

14 Jul 2012

Stress management program may help people with MS prevent new disease activity

A new study shows that taking part in a stress management program may help people with multiple sclerosis (MS) prevent new disease activity. The study is published in the July 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

Physicians need to know how chemical intolerance affects people: Study

Chemical intolerance contributes to the illnesses of 1 in 5 patients but the condition seldom figures in their diagnosis, according to clinical research directed by a UT Medicine San Antonio physician.

11 Jul 2012

Fatal outcome from HFMD is rare, says LUHS pediatric infectious disease specialist

A mysterious disease that has killed nearly 60 children in Cambodia has been identified by the World Health Organization as enterovirus 71. This virus is one among a family of viruses that cause a variety of illnesses, including a common childhood illness called hand, foot and mouth disease, but Andrew Bonwit, MD, pediatric infectious disease specialist at Loyola University Health System, says a fatal outcome from such illness is rare.

11 Jul 2012

Iron supplementation decreases fatigue by almost 50% in nonanemic women

Iron supplementation reduced fatigue by almost 50% in women who are low in iron but not anemic, according to the results of a clinical trial published July 9 in CMAJ (Canadian Medical Association Journal).

10 Jul 2012

EGF helps prevent inflammation-induced cancer

Epidermal growth factor (EGF) is a protein that normally regulates intestinal healing. However, biological therapies, like EGF, also may pose the risk of increasing the possibility of cancer. Philip Dubé, PhD, and Brent Polk, MD, both of the Saban Research Institute of Children's Hospital Los Angeles have demonstrated that in preclinical models, EGF encourages healing and provides powerful anti-inflammatory properties that prevent inflammation-induced cancer.

10 Jul 2012

Questionnaire may aid rheumatoid arthritis flare diagnosis

French researchers have created a 13-item patient-administered questionnaire for identifying a recent or present rheumatoid arthritis flare.

9 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

Fingolimod offers minor added benefit for patients with RRMS

The immunosuppressive drug fingolimod (trade name: Gilenya-) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed whether fingolimod offers an added benefit compared with the present standard therapy.

6 Jul 2012

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies.

5 Jul 2012

Children at increased risk for heat-related illness

Extreme heat continues to plague the nation with many areas seeing record temperatures. Though everyone needs to take precautions when it comes to dangerous heat, it's especially important to watch your kids. Children are at a greater risk than adults of sustaining a heat injury.

4 Jul 2012

Fighting the physical consequences of jet lag in elite athletes

Research suggests that having a good understanding of preflight, in-flight, and postflight management options helps clinicians, athletes, and coaches minimize the adverse consequences of travel fatigue and jet lag on elite athletic performance.

2 Jul 2012

Current diagnosis and treatment approaches for rheumatoid arthritis

In the realm of deadly and disabling diseases, conditions such as cancer and Alzheimer's seem to attract the most media attention. But there are others that take a similarly high toll, and rheumatoid arthritis is one of them, Mayo Clinic researchers say. It is a common cause of disability: 1 of every 5 rheumatoid arthritis patients is unable to work two years after diagnosis, and within five years, that rises to one-third. Life expectancy drops by up to five years.

2 Jul 2012